» Articles » PMID: 38778921

Evolving Challenges in the Implementation of China's "Four Frees and One Care" Policy for HIV/AIDS

Overview
Publisher Dove Medical Press
Specialty Public Health
Date 2024 May 23
PMID 38778921
Authors
Affiliations
Soon will be listed here.
Abstract

In response to the HIV/AIDS epidemic, China initiated the "Four Frees and One Care" policy in late 2003. This policy provided free counseling, testing, and antiretroviral treatment for people living with HIV, while also offering support to affected families. While instrumental in advancing HIV/AIDS prevention, the policy faces evolving challenges. This study aims to analyze this challenge from multiple dimensions and, based on this analysis, provide effective recommendations for the Chinese government to address it, promoting the sustainable development of the "Four Frees and One Care" policy. The research found that reduced government funding has led to the decline of grassroots organizations, creating a disconnect between administrative and treatment systems. Additionally, advancements in medical technology introduce new antiretroviral drugs, complicating their integration into the healthcare system. In the current healthcare reform, updating the list of free antiretroviral drugs proves challenging. Adapting the policy to contemporary HIV/AIDS prevention should be a priority for the Chinese government. Balancing financial constraints, organizational sustainability, and evolving medical technologies will be pivotal for the ongoing transformation of the "Four Frees and One Care" initiative.

References
1.
Zakumumpa H, Kiweewa F, Khuluza F, Kitutu F . "The number of clients is increasing but the supplies are reducing": provider strategies for responding to chronic antiretroviral (ARV) medicines stock-outs in resource-limited settings: a qualitative study from Uganda. BMC Health Serv Res. 2019; 19(1):312. PMC: 6521347. DOI: 10.1186/s12913-019-4137-7. View

2.
Ancker S, Rechel B . HIV/AIDS policy-making in Kyrgyzstan: a stakeholder analysis. Health Policy Plan. 2013; 30(1):8-18. DOI: 10.1093/heapol/czt092. View

3.
Ballreich J, Levengood T, Conti R . Opportunities and Challenges of Generic Pre-Exposure Prophylaxis Drugs for HIV. J Law Med Ethics. 2022; 50(S1):32-39. PMC: 9341204. DOI: 10.1017/jme.2022.33. View

4.
Zhang H, Han M, Zhou Y, Xiu X, Xu F, Wang L . [Interrupted time series analysis for influence on HIV related fatality of implementation of 'Four Free Services One Care' policy in China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020; 41(3):406-411. DOI: 10.3760/cma.j.issn.0254-6450.2020.03.024. View

5.
Dou Z, Luo Y, Zhao Y, Zheng X, Han M . Trends in Mortality and Prevalence of Reported HIV/AIDS Cases - China, 2002-2021. China CDC Wkly. 2023; 5(42):943-947. PMC: 10646163. DOI: 10.46234/ccdcw2023.177. View